Provides laboratory tests that connect results with patients’ clinical data, using artificial intelligence to help physicians tailor care, and licenses de-identified health data and clinical-trial support to pharmaceutical and biotechnology companies.
10-K for FY2025, filed Feb 24, 2026We endeavor to unlock the true power of precision medicine by creating Intelligent Diagnostics through the practical application of…View ↗
Our Diagnostics product line leverages our laboratories to provide NGS diagnostics, PCR profiling, and other anatomic and molecular…View ↗
Our Data and applications product line facilitates drug discovery and development for life sciences companies through multiple products…View ↗
For clinical tests, Tempus is paid by Medicare, Medicaid and commercial insurers after claims are processed, generally 30-120 days after service; direct-bill customers usually pay 30-60 days after invoice. Drug and biotechnology customers pay for data licenses and clinical-trial services, generally 60 to 90 days after service.
10-K for FY2025, filed Feb 24, 2026For clinical orders from Medicare, Medicaid, and commercial insurance, the Company determines transaction price by reducing the standard…View ↗
For direct bill orders from research institutions, pharmaceutical companies, or other third parties, the Company determines the transaction…View ↗
Data and applications revenue primarily represents data licensing and clinical trial services that the Company provides to pharmaceutical…View ↗
For Insights, Trials and Next arrangements, pricing is fixed and the Company may be compensated through a combination of an upfront payment…View ↗
10-K for FY2025, filed Feb 24, 2026
FY2025 revenue by product or service ↗$1.3B
10-K for FY2025, filed Feb 24, 2026
$1.3B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Diagnostics
Sold outright
10-K for FY2025, filed Feb 24, 2026 |
75% |
Diagnostics, FY2025
$955.4M Sources
|
Sold outright |
|
Data and applications
|
25% |
Data and applications, FY2025
$316.4M Sources
|
Healthcare providers order laboratory tests, with clinical testing billed to insurers and government programs; research institutions and other parties can pay directly for tests. Pharmaceutical and biotechnology companies also buy licensed data and clinical-trial services.
10-K for FY2025, filed Feb 24, 2026Our Diagnostics product line leverages our laboratories to provide NGS diagnostics, PCR profiling, and other anatomic and molecular…View ↗
The Company derives revenue from selling lab services (“Diagnostics”) to physicians, genetic counselors, academic research institutions…View ↗
The Company generally recognizes revenue for its Diagnostics product offering when it has met its performance obligation relating to an…View ↗
For direct bill orders from research institutions, pharmaceutical companies, or other third parties, the Company determines the transaction…View ↗
Data and applications revenue primarily represents data licensing and clinical trial services that the Company provides to pharmaceutical…View ↗
No. It lost $245M in FY2025.
10-Q for Q3 FY2026, filed Nov 2, 2026
−$14.9MView ↗
10-Q for Q3 FY2026, filed Nov 2, 2026
Open tableView ↗
8-K, filed Jul 30, 2026
Total revenue of $382.5 million, up 22% year-over-year Oncology volume growth of 31% year-over-year, up from 28% last quarter Molecular…View ↗
8-K, filed Jul 20, 2026
On July 20, 2026, Tempus AI, Inc., a Nevada corporation (“Tempus”), entered into an Agreement and Plan of Merger (the “Merger Agreement”)…View ↗
Competes with Foundation Medicine, Roche Holdings, Caris Life Sciences, Guardant Health, Natera, Neogenomics, ResolutionBio, Agilent, Quest, LabCorp, Myriad Genetics, Genomind, GeneDx, Variantyx, Baylor Genetics, Flatiron Health, IQVIA Holdings, ConcertAI, Fortrea, and ICON
10-K for FY2025, filed Feb 24, 2026Our Diagnostics product line primarily faces competition from diagnostics companies that profile genes in cancers and other disease areas…View ↗
Loading...